Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Non-Small Cell Lung Cancer

19 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Basic Science

    VICCMEL15137

    07/21/2015

    Characterizing the Cardiometabolic Implications of Immune Therapy

    Basic Science

    VICCTHO0547

    12/19/2005

    Molecular Fingerprints in Lung Cancer: Predicting Tumor Response to Therapy (SPORE)

    Basic Science

    VICCTHO0398

    12/04/2003

    Molecular Predictors of Lung Cancer Behavior. (SPORE)

    Basic Science

    VICCTHO0136

    05/01/2001

    Molecular Fingerprinting of Lung Cancer (SPORE)

    Other

    ECOGTHOA151216

    09/17/2015

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    Treatment

    VICCTHO1625

    06/01/2016

    An Open-Label, Single Arm Phase II Study of Nivolumab in Combination with Ipilimumab as First Line-Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    ECOGTHOS1403

    04/26/2016

    A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

    Treatment

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    VICCTHO1573

    02/01/2016

    An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    VICCPHI1598

    12/10/2015

    A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 with seribantumab (MM-121), istiratumab (MM-141), or trametinib in biomarker-selected cancer patients

    Treatment

    VICCPHI1588

    11/27/2015

    A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

    Treatment

    VICCTHO1521

    10/16/2015

    A Phase III, Open-Label, Randomized, Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or CARBOPLATIN for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer

    Treatment

    ECOGTHOE4512

    09/15/2015

    A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

    Treatment

    ECOGTHOS1400

    04/02/2015

    Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

    Treatment

    VICCTHO1443

    03/11/2015

    A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

    Treatment

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    VICCTHN1244

    07/25/2012

    Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

    Treatment

    ECOGTHO5508-M

    02/09/2011

    Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

    Treatment

    ECOGTHOE1505-M

    07/27/2007

    A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)


    Print this page for your doctor